Prostaglandin E2 Secretion and Effect on Adipocyte Lipogenesis by Wortman, Patrick Allen
University of Tennessee, Knoxville 
TRACE: Tennessee Research and Creative 
Exchange 
Masters Theses Graduate School 
12-2004 
Prostaglandin E2 Secretion and Effect on Adipocyte Lipogenesis 
Patrick Allen Wortman 
University of Tennessee, Knoxville 
Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes 
 Part of the Nutrition Commons 
Recommended Citation 
Wortman, Patrick Allen, "Prostaglandin E2 Secretion and Effect on Adipocyte Lipogenesis. " Master's 
Thesis, University of Tennessee, 2004. 
https://trace.tennessee.edu/utk_gradthes/4825 
This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and 
Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE: 
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu. 
To the Graduate Council: 
I am submitting herewith a thesis written by Patrick Allen Wortman entitled "Prostaglandin E2 
Secretion and Effect on Adipocyte Lipogenesis." I have examined the final electronic copy of this 
thesis for form and content and recommend that it be accepted in partial fulfillment of the 
requirements for the degree of Master of Science, with a major in Nutrition. 
Naima Moustaid-Moussa, Major Professor 
We have read this thesis and recommend its acceptance: 
Jay Whelan, Betsy Haughton 
Accepted for the Council: 
Carolyn R. Hodges 
Vice Provost and Dean of the Graduate School 
(Original signatures are on file with official student records.) 
To the Graduate Council: 
I am submitting herewith a thesis by Patrick Allen Wortman entitled "Prostaglandin E2 
secretion and effect on adipocyte lipogenesis". I have examined the final paper copy of 
this thesis for form and content and recommend that it be accepted in partial fulfillment 
of the requirements for the degree of Master of Science, with a major in Nutrition. 
We have read this thesis and 
recommend its acceptance: 
Accepted for the Council: 

Prostaglandin E2 secretion 
and effect on adipocyte lipogenesis 
A Thesis 
Presented for the 
Masters of Science 
Degree 
The University of Tennessee, Knoxville 
Patrick Allen Wortman 
December 2004 
DEDICATION 
This thesis is dedicated to my wife, Leslie J. Wortman, whose support and dedication 
were essential for me to achieve this milestone in my life. She encouraged me to return 
to school, was there for me when the journey got difficult, and shared equally in the 
celebrations and disappointments. Thank you for your unconditional love and the many 
sacrifices you have made to allow me to reach this goal. 
Thank you also to my mother, Sara Lawson, for the values she instilled in me and the 
love and support she has provided over the years. 
11 
ACKNOWLEDGEMENTS 
I would like to thank all the individuals who have supported and educated me 
during my time here at the University of Tennessee. Most importantly, I would·like to 
thank Dr. Naima Moustaid-Moussa for support that goes beyond my capacity to describe 
here. She gave me my start in research and ensured I had every opportunity available to 
grow as a researcher and expand my horizons. Without her support and mentoring, I 
have no doubt I would not be writing this today. 
I would also like to thank Dr. Jay Whelan, one of the best teachers I have ever 
known, for infecting me with his passion. Your expertise and depth of knowledge have 
been invaluable in assisting me in my-studies and my research .. · 
I would like to thank Dr. Betsy Haughton for her insight, and for keeping me 
focused on why we conduct research. 
I owe a tremendous debt of gratitude to several of my lab members. Dr: Suyeon 
Kim, Dr. Sumi Urs, and Rashika Joshi each contributed immeasurably to this work by 
teaching me laboratory techniques �d methods. To Suyeon a special:th� you,-as she 
took me under her wing as a brand new lab assistant and helped me get started. Thank 
you to Allison Stewart for her help as well. Special thanks to Arnold Saxton for his help 
and time in statistical analysis of micro array data. 
I would like to thank my wonderful wife Leslie fo� her years of sacrifice. She has 
put most of her goals and ambitions on hold to allow me to pursue my education, and for 
this I am eternally grateful. 
Finally, I would like to thank all my family members ·who overwhelmed n�e with · 
their show of suppo� by being p�esent at �y defens�. Tim and Marla, it is an honor and 
a privilege to have· you as·family. 
. . . .  
11l 
• r • • : • •  
. · .' ·: . · .  
ABSTRACT 
With the current focus on the role of n-3 PUF As as beneficial dietary interventions in the 
fields of cardiovascular disease and cancer, there has been a vastly increased awareness 
and focus on the mechanism of action for these essential fatty acids. 
Many of the effects of PUF As are mediated via changes in prostaglandin (PG) levels. One primary substrate for PGs is arachidonic acid (AA) (20:4 n-6), which results 
in the production of 2-series PGs. Increased concentrations of AA have been shown to increase levels of PGE2 in vitro and in vivo. The omega-3 fatty acid EPA (20:5 n-3) is of particular interest due to its incorporation into cell membrane phospholipids in 
competition with AA. EPA can also serve as a substrate for prostaglandin production 
when present in tissue and results in the production of 3-series PGs, which do not appear 
to produce the same effects as 2-series PGs, although data is extremely limited. The 
secretion of prostaglandins (PGs ), and specifically PGE2 has been demonstrated in human and rodent adipocytes, and the presence of PGE2 receptors in these tissues has also been demonstrated. PGE2 can act in an autocrine/paracrine fashion in adipocytes to decrease lipolysis via G-protein coupled receptors. Preliminary data from our lab on Ape Mini+ 
mice showed that cyclooxygenase (COX) inhibition significantly reduced the activity of fatty acid synthase (FAS) in adipose tissue, and PGE2 receptor agonists partially but significantly reversed this effect. Our overall objective was to determine whether treatment with EPA or selective COX-2 inhibitors would lead to a reduction in measured PGE2 that would in tum regulate markers of lipogenesis. We hypothesized that increased levels of EPA would competitively reduce tissue AA levels, and consequently PGE2 production, leading to decreased activity of markers specific to adipogenesis, specifically the FAS enzyme. 
Selective COX-2 inhibition was expected to produce similar effects via inhibition of 
COX metabolism of AA to PGs. Studies were conducted on 3T3-Ll adipocytes. Dose­
response studies demonstrated a clear relationship between increasing doses of EPA or 
AA and measured PGE2/PGE3 levels. Manipulation of PGE2 levels via addition of EPA to culture media led to significant changes in measured PGE2 levels versus AA, but did not result in a significant decrease in FAS enzyme activity. Addition of celecoxib, a 
lV 
selective COX-2 inhibitor (CI), to culture media resulted in a significant decrease in 
PGE2 levels and FAS activity. Addition of exogenous PGE2 to CI treatment did not 
reverse the decreased FAS enzyme activity. These results indicate that addition of EPA 
can displace AA in cell membrane phospholipids and reduce PGE2 production, but does 
not impact FAS activity. Suppression of PGE2 by selective COX-2 inhibition does lead 
to decreased FAS activity, which is not reversed by exogenous PGE2 addition. 
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Obesity rates in the United States continue to increase at an alarming rate despite 
increasing attention from medical professionals, government officials and the media regarding the seriousness of this problem. The most current statistics indicate that 64.5% 
of Americans are overweight (BMI � 25), and that 30.5% of those who are overweight 
can be classified as obese (BMI � 30) [l ]. The direct impact of this problem is related to 
the increased risk of disease and mortality since obesity is a known risk factor for heart disease, hypertension, diabetes and some cancers [2]. The indirect implications of this 
epidemic of excess weight have manifested as a crippling financial burden to our 
healthcare system. For example, obesity-attributable medical expenditures were estimated to be $75 billion in 2003 dollars with approximately one-half of these expenses 
paid by Medicare and Medicaid [3]. 
Recent work in the fields of cardiovascular disease and cancer has demonstrated a 
possible role for omega-3 fatty acids as beneficial dietary interventions, and as a result 
has greatly increased scientific and public awareness of these essential polyunsaturated fatty acids (PUF As) [ 4-7]. One of the cornerstones for decreasing adiposity has been the 
recommendation to decrease caloric intake by lowering fat intake due to its high calorie 
density [2, 8]. This emphasis on low fat diets, although sound from a calorie intake 
standpoint, may have led to an inadvertent decrease in the consumption of essential fats, 
such as omega-3 fatty acids, in the typical American diet. Many of the effects of these omega-3 PUFAs are mediated via changes in prostaglandin (PG) levels [ 4, 9-11]. PGs are chemical messengers derived from PUF As selectively cleaved from the sn-2 position of cell membrane phospholipids [9] (see fig. 4 
on page 12). Prostaglandin E2 (PGE2) is of particular interest in the area of energy metabolism and obesity, since it has been shown to decrease lipolysis, or triacylglycerol 
breakdown [12, 13], and potentially increase the activity of the fatty acid synthase (FAS) 
enzyme resulting in increased endogenous fatty acid production. One primary substrate 
for PGs is arachidonic acid (AA) (20:4 n-6), which results in the production of 2-series 
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PGs [4] such as PGE2. Increased concentrations of AA have been shown to increase 
levels of PGE2 in vitro and in vivo [5, 14]. 
The omega-3 fatty acid eicosapentaenoic acid (EPA) (20:5 n-3) is also 
incorporated into cell membrane phospholipids in direct competition with AA [ 15]. EPA 
can serve as a substrate for prostaglandin production when present in tissue and results in 
the production of 3-series PGs, which appear to produce weaker effects when compared 
to the 2-series PGs, although data remain extremely limited [ 16]. 
In addition to competitive inhibition with EPA, PG formation can also be 
inhibited via inhibition of the COX pathway [17-20]. The use of both non-selective COX 
inhibitors and selective COX-2 inhibitors has been shown to decrease PGE2 secretion in 
adipocytes [ 12, 21-23]. This pharmacological intervention represents a means to 
precisely target PGE2 metabolism to assist in understanding the role it plays in adipocyte 
metabolism. 
Available data suggests the possibility of impacting aspects of lipid metabolism 
by manipulating PGE2 levels. Accordingly, the goal of this research is to utilize EPA or 
celecoxib (selective COX-2 inhibitor) to inhibit AA metabolism to PGE2 and determine 
the effect on markers of adipocyte lipogenesis. 
More specifically our aims are: 
1. To determine if the endogenous production of PGE2 can be decreased by the 
addition of exogenous EPA or selective COX-2 inhibitor to cultured adipocytes. 
2. To determine if a decrease in endogenous PGE2 production by adipocytes results 
in a decrease in markers of lipogenesis, specifically the activity of the FAS 
enzyme. 
Findings from this project may provide a foundation for further research that will help 
clarify: 1) The role for interventions aimed at decreasing PGE2 synthesis in reducing 
lipogenic activity in adipocytes and 2) The public health recommendations for omega-3 
fatty acids, and specifically for EPA, in the diet of Americans, including the potential 





A. Incidence and Implications 
Body mass index (BMI) is the most consistently used measure to indicate excess 
weight, and is defined as weight in kilograms divided by height in meters squared { weight in kg / (height in meters )2 } [2]. BMI is now universally used since the World 
Health Organization (WHO) recommendations and National Institutes of Health (NIH) 
report in 1997 and 1999, respectively [24, 25]. Although less accurate in certain 
populations, such as athletes, children and the elderly [26], BMI correlates well with both 
morbidity and mortality for most adults and provides a convenient, non-invasive and 
affordable tool in the clinical setting to classify overweight and obesity (Table 1) [2]. 
In recent years the incidence of overweight and obesity has received tremendous 
attention as these conditions have reached epidemic proportions in the United States as 
well as other countries. This is evidenced by a large volume of resources being invested 
into understanding the processes involved as well as the interventions that can most effectively halt and/or reverse these conditions. The most current statistics indicate that 
64.5% of Americans are overweight (BMI � 25), and that 30.5% of those who are overweight can be classified as obese (BMI � 30) [1]. 
With increased weight comes increased risk of death and disease. For the average middle-aged adult, an excess of 10-20 pounds can increase the risk of mortality [27]. Younger adults are more impacted by excess weight than older adults, as indicated by 
data showing greater years of life lost to obesity than older adults [28]. Being overweight or obese is also implicated as a risk factor in several disease states, including diabetes, 
heart disease, hypertension, some cancers, and stroke [26], all of which contribute to the 
increased risk of death (Table 2) [29]. Recently it has been reported that approximately 
400,000 deaths per year can be attributed to obesity related causes [30]. This makes 
obesity second only to smoking as a cause of preventable death in the U.S. 
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Table 1. Classification of Overweight and Obesity by BMI 
Classification Obesity Class BMI (kg/m
2
) 
Underweight --- <18.5 
Normal --- 18.5-24.9 
Overweight --- 25.0-29.9 
Obesity I 30.0-34.9 
II 35.0-39.9 
Extreme Obesity III �40 
National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and 
Treatment of Overweight and Obesity in Adults: the evidence report 
Table 2. Rank of Selected Conditions in 2001 Leading Causes of U.S. Deaths 
Rank Condition Number of Deaths Percent of Total 
1 Heart Disease 700,142 29 2 Cancer 553,768 22.9 3 Stroke 163,538 6.8 6 Diabetes 71,372 3.0 
14 Essential Hypertension 19,250 0.8 
Anderson, R.N., A.M. Minino, L.A. Fingerhut, M. Warner, and M.A. Heinen. Deaths: injuries, 2001. Natl 
Vital Stat Rep., 2004. 52(21) 
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Research has shown that obese individuals have 36% higher average medical 
expenditures when compared to normal weight individuals [31]. Estimates of U.S. 
obesity-attributable medical expenses were $75 billion for 2003, with approximately one­
half of these financed by Medicare and Medicaid [3]. As the number of overweight and 
obese individuals continues to climb, so will the burden placed on financial and medical 
resources of the U.S. 
B. Causative Factors 
The etiology of obesity is complex and multi-factorial including genetic, 
metabolic, environmental and behavioral factors [32]. Since genetic factors are 
predetermined, the primary factors that are controllable, and thus the target for 
intervention, are environmental and behavioral factors. Lifestyle modifications, and 
more specifically increasing activity while maintaining or decreasing caloric intake, are 
the cornerstones of the current effort to reduce the incidence of overweight and obesity 
[2, 26]. In 1998 it was estimated that 29% of adult Americans were sedentary, 44% 
participated in some physical activity but still did not meet the recommended 30 minutes 
of activity on most days, and only 27% of adults actually achieved the recommended 
amount of activity [33]. In addition to the limited activity prevalent in our society, 
caloric intake has also increased. During the time period from 1971-2000, average 
energy intake for men increased from 2,450 calories to 2,618 calories, and energy intake 
for women increased from 1,542 calories to 1,877 calories, with more recent data 
indicating that this trend has continued [34]. These specific lifestyle factors, coupled 
with other environmental influences on the genetics of obesity, have been the driving 
force behind the epidemic that now faces our nation [35]. 
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II. POLYUNSATURATED FATTY ACIDS 
A. Description and Metabolism 
Fatty acids (FAs) are molecules that are composed of hydrocarbons with a methyl 
end (C-CH3) and a carboxylic acid end (C-COOH). One means of classification of these fatty acids is relative to the number of double bonds. Polyunsaturated fatty acids 
(PUF As) are F As that contain two or more double bonds. From a nutrition standpoint, there are two sub-classes of PUF As that are considered essential due to the proximity of 
the double bond to the methyl end, also called the omega end. Omega-3 fatty acids have 
the first double bond 3 carbons away from the omega end, thus the designation omega-3 
and often written n-3. Omega-6 fatty acids have the first double bond 6 carbons away 
from the omega end and are thus termed omega-6 (n-6) (Fig. 1 ). 
These two classes ofFAs are essential for humans and must be obtained from the 
diet due to the lack of the enzymes necessary to add these double bonds to fatty acids without them. The two primary essential F As in the American diet include the n-6 
linoleic acid (LA) and the n-3 alpha-linolenic acid (ALA) since they can be metabolized into the longer bioactive arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). In the United States, PUF As contribute approximately 7% 
of total energy intake and 19-22% of the energy intake from fat. LA, the primary n-6 PUFA consumed, compromises 84-89% of the total energy from PUFAs (36]. ALA is the primary n-3 fatty acid consumed, and makes up approximately 0. 7% of total energy from PUF As [36]. 
LA is converted to y-linolenic acid (GLA, 18:3 n-6) via the Li-6 desaturase 
enzyme, and subsequently converted to AA through the intermediate dihomo- y-linolenic 
acid (DGLA, 20:3 n-6) via successive steps involving the elongase and Li-5 desaturase 
enzymes. Following the same pathway, ALA is converted to EPA via the intermediates 
stearidonic acid (18:4 n-3) and eicosatetraenoic acid (20:4 n-3). This pathway then 
continues through further elongation, desaturation, and peroxisomal P-oxidation to 
produce docosahexaenoic acid (22:6 n-3) as a final end product (Fig. 2). 
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H3C 
Omega end LA (18:2, n-6) Omega-6 
ALA (18:3, n-3) Omega-3 
Figure 1. Linoleic Acid and Alpha-Linolenic Acid 
n-6 Family 
Linoleic acid ( 1 8  :2 n-6) 
't A-6 Desaturase 
y-Linolenic acid ( 1 8 :3 n-6) 
't Elongase 
n-3 Family 
a-Linolenic acid ( 1 8 :3 n-3) 
Stearidonic acid ( 18 :4 n-3) 
COOH 
COOH 
Dihomo y-Linolenic acid (20:3  n-6) Eicosatetraenoic acid (20 :4 n-3) 






Eicosapentaenoic acid (20 :5  n-3) 
Docosahexaenoic acid (22 :6 n-3) 
Figure 2. Arachidonic Acid and Eicosapentaenoic Acid Synthesis 
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The rate-limiting enzyme for this pathway is 6-6 desaturase [37], and this aspect is 
critical from a nutritional standpoint. Since LA and ALA compete for this enzyme, and since the majority of the PUFA intake in the U.S. is made up of the n-6 fatty acid LA, the 
fatty acids produced in this pathway are skewed towards members of the n-6 family, with 
AA the predominate end product [38, 39]. Increasing intake of the n-3 fatty acid ALA is 
often recommended to competitively inhibit the production of AA, and has been shown to 
be moderately successful in some studies [15, 40, 41], although there is some evidence 
that even when consumed in a 1 : 1 ratio the tissue levels of n-6 fatty acids may exceed the 
tissue levels of n-3 fatty acids [42]. A second, and possibly more effective, means of 
reducing tissue levels of AA is to consume the preformed n-3 fatty acid EPA, which has been shown to compete with AA for incorporation into cell membrane phospholipids 
leading to increased levels of EPA [43-45]. The effectiveness of this strategy may depend on the foods from animal sources that make up an individual's diet, as studies in 
mice have shown that when preformed AA and EPA were fed in equal amounts, tissue phospholipids contained higher concentrations of AA [14]. 
B. Role In Weight Loss 
Replacement of AA with fatty acids of the n-3 family in tissue phospholipids, and 
specifically EPA, is one of the mechanisms on which the recommendations for increasing consumption of these PUF As are based [ 6]. AA serves as a substrate for the action of 
several enzymes that produce eicosanoids, specifically PGs, thromboxanes (TXs ), hydroxyeicosatetraenoic acids (HETEs), and leukotrienes (LTs) [4]. These eicosanoids serve as chemical messengers in intracellular and intercellular signaling, and many of the 
eicosanoids produced from AA have been implicated in inflammation and diseases states 
such as cancer [5, 10, 43, 46-48]. EPA can be metabolized by the same enzymes as AA 
producing similar but distinct eicosanoids which appear to have weaker action with 
regards to inflammation [16, 43, 49, 50]. Although the impact on inflammation is a 
major focus for the role of n-3 fatty acids, it is not the only means by which these PUFAs may impact disease conditions. 
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There is an increasing body of evidence that PUF As themselves may impact 
disease conditions, and specifically the conditions of overweight and obesity. This 
impact is most likely a combination of the physiological, biochemical, and genetic effects 
of these fatty acids. From a physiological standpoint, dietary n-3 fatty acids increase cell 
membrane permeability [ 51], possibly influencing the selectivity and rate of substances 
crossing the membrane. In addition, PUF As can reduce the triglyceride accumulation in 
skeletal muscle [52], and may impact accumulation in other tissues as well, which is 
associated with improvements in insulin sensitivity [52, 53]. 
From a biochemical standpoint, dietary PUF As impact eicosanoid levels as 
discussed above with a wide range of consequences. In addition, PUF As modulate the 
activity and gene expression of several proteins in either an eicosanoid-dependent or 
independent manner [54]. For example, PUFAs appear to impact leptin levels in a 
manner that may be independent of eicosanoid secretion [55-57]. Leptin is a hormone 
secreted by adipocytes that impacts food intake, energy expenditure, and energy balance 
while also potentially impacting insulin sensitivity and diabetes. Increased levels of 
circulating leptin are associated with decreased food intake, increased thermogenesis, and 
decreased adipose tissue mass [58]. Growing evidence suggests that leptin may be 
implicated in a variety of pathophysiologies associated with obesity, making it a focus in 
the battle against this epidemic. Rats fed diets high in n-6 or n-3 fatty acids had 
significantly higher leptin levels versus animals fed beef tallow, independent of fat mass 
[55]. In vitro, EPA was shown to significantly increase leptin secretion and mRNA 
expression in 3T3-Ll adipocytes [56]. Studies in rat and obese human adipose tissue 
explants showed that exposure to the AA metabolite PGE2 from exogenous sources 
increased leptin levels [ 12, 59]. In contrast, AA was shown to decrease leptin secretion 
and mRNA expression in isolated rat adipocytes through a prostaglandin-independent 
mechanism [57]. Given this wide range of contrasting effects on leptin, the exact role 
and mechanism of PUF A action remains to be clarified. 
The most powerful and well-studied role for PUF As in the battle against excess 
weight is their impact on gene expression. Peroxisome proliferator-activated receptors 
(PPARs) and sterol regulatory element binding proteins (SREBPs) have emerged as the 
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key targets that mediate PUF A effects. Both have affinity for one or more PUF As, and impact genes involved in lipogenesis or lipolysis. 
PP ARs are transcription factors belonging to the superfamily of nuclear receptors 
and exist in three isoforms (a, o, y). They recognize and bind DNA response elements as 
heterodimers with nuclear retinoic acid receptors (RXRs). Activation of PP ARs impacts 
several genes related to adipocyte development and metabolism [60]. PPAR- a is highly 
expressed in hepatocytes, cardiomyocytes, skeletal muscle, and enterocytes, and is the key player from a weight loss perspective as this isoform primarily promotes lipid 
oxidation [�1]. PUFAs have been shown to act as ligands for all three isoforms, with 
the affinity for PP AR-a being the greatest [62-64]. In the liver, activation of PP AR-a 
induces the expression of transport proteins and enzymes involved in lipid oxidation and 
thermogenesis including camitine palmitoyltransferase, peroxisomal acyl-CoA oxidase and uncoupling protein-3 [65-67]. The net result of these changes is to increase the use 
of fatty acids as fuel in mitochondria and peroxisomes and improve glycemic control. 
This was demonstrated in PP AR-a knockout mice, which developed characteristics of 
adult-onset diabetes such as fatty livers, elevated blood triglycerides, and hyperglycemia during periods of food deprivation [68]. Less is known at this time regarding PPAR-o, 
but some evidence indicates that it may function in a manner similar to PP AR-a [69]. 
SREBPs are a family of membrane-bound transcription factors that regulate 
cholesterol and fatty acid homeostasis, with three isoforms ( l a, l e, 2) identified as well. 
PUF As have been shown to suppress expression of SREBPs (70-72]. SREBP-2 appears 
to be involved primarily in cholesterol metabolism with only minor involvement in fatty acid metabolism [73]. The SREBP-1 isoforms (a, c) are derived from the same gene, 
which undergoes alternative splicing to produce the isoforms [74]. The la  isoform is a 
much more potent activator of transcription than the l e  isoform [75], but the l e  form 
predominates in liver and adipocytes, although both forms are present (76]. Both 
isoforms have demonstrated a role in increasing lipogenic genes in liver and adipose 
tissue such as acetyl-CoA-carboxylase (ACC), FAS, and L-pyruvate kinase [71, 75, 77]. 
They have also been implicated in adipocyte hypertrophy [77]. Increased dietary intake of PUF As would therefore lead to increasing expression of genes associated with 
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lipolysis and decreasing expression of genes associated with lipogenesis and a net benefit 
of decreased adiposity (Fig. 3). It is still uncertain whether SREBPs and PPARs work 
through the same pathway or distinct pathways, with both possibilities still under 
investigation. 
III. ARACHIDONIC ACID METABOLISM 
A. The Arachidonic Acid Cascade 
Arachidonic acid obtained from diet or synthesized from LA is incorporated into 
cell membrane phospholipids. AA can be subsequently cleaved from these phospholipids 
by the action of various phospholipases, primarily cytosolic phospholipase A2 ( cPLA2) 
(fig. 4). This occurs when cPLA2 binds to the membrane phospholipid and cleaves the 
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Figure 3. Impact of PUFAs On Gene Expression 
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Figure 4. Metabolism of Arachidonic Acid 
This initial step is also the rate-limiting step in the metabolism of AA. Liberated AA can 
then serves as a substrate for cyclooxygenase (COX) resulting in the production of 
prostaglandins of the 2 series [ 1 O]. 
B. Cyclooxygenase 
COX ( also called prostaglandin synthase) catalyzes the initial step in the 
formation of prostaglandins from the AA precursor via two distinct, sequential 
biochemical reactions [78]. The initial step converts AA via cyclooxygenase activity to 
the unstable PGG2, a peroxide intermediate. PGG2 then migrates to the peroxidase active 
site where it is further metabolized to PGH2, which is the parent compound for the 
production of PGs and TXs (Fig. 4). COX exists in two isoforms, designated COX-1 and 
COX-2. COX- 1 is found in most tissues and is constitutively expressed. It is considered 
a housekeeping enzyme with a role in maintaining tissue integrity. This function is of 
particular importance in the gastrointestinal (GI) tract, and is largely responsible for the 
increased incidence of ulcers and other GI complaints associated with the use of non­
specific COX inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDs) [79]. 
COX-2 is considered an inducible enzyme and is stimulated by growth factors, 
inflammatory cytokines, and tumor promoters [ 1 7] ,  although it is found normally in 
1 2  
tissues such as the kidneys [80]. COX-2 is highly homologous to COX-1, with 61 % of the amino acids identical and 84% similar. The relevant difference between the isoforms 
is a slightly larger active site that forms a pocket on the COX-2 enzyme [79]. This has 
been the key to the development of the class of specific COX-2 inhibitors such as 
rofecoxib, celecoxib, and NS 398 [79]. 
The presence of COX has been demonstrated in preadipocytes and adipocytes [81, 
82]. RT-PCR analysis of mRNA in Obl 771 preadipose cells and mature adipocytes demonstrated that both COX isoforms were present in these cells, with COX-1 present in 
much higher quantities. The levels of both forms decreased markedly during the differentiation process, with COX-1 decreasing approximately 98%, resulting in lower 
levels in adipocytes when compared to preadipocytes [21, 82]. The development of COX-1 and -2 knockout mice has brought to light a dynamic relationship between these 
two enzymes. Compared to wild-type mice, the knockout mice expressed the remaining 
functional COX gene at higher levels and both knockout models expressed 6-8 fold 
higher levels of basal PGE2 versus the control mice [83]. In addition, evidence from COX knockout mice indicates that COX-2, when expressed, may be the primary enzyme 
involved in PGE2 production in many tissues [22, 83]. 
C. The Role of EPA 
The role of EPA in AA metabolism is one of direct competition. Consumption of 
preformed EPA bypasses the biosynthetic pathway, allowing increased concentrations to be available for incorporation into cell membrane phospholipids. The similarity in structure of these two fatty acids (Fig. 5) allows EPA to readily substitute for AA in the sn-2 position of triacylglycerols that constitute the cell membrane. Numerous studies have demonstrated that feeding preformed EPA results in higher levels in plasma and tissue phospholipids, with a concomitant decrease in levels of AA [5, 15, 84, 85]. Once 
incorporated into tissue phospholipids, EPA appears to be mobilized preferentially [86-
88], and then competes with AA as a substrate for the COX enzymes. EPA is a poor 
substrate for both COX enzymes compared to AA [89], but is more efficiently 
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COOR 
Arachidonic Acid (n-6) 
· ·  COOR 
Eicosapentaenoic Acid (n-3) 
Figure 5. Structural Similarities of AA and EPA 
metabolized by COX-2 [90]. Despite being a poor substrate, much evidence exists that 
the availability of EPA leads to decreased production of metabolites of AA [5, 16, 91, 92] via displacement of AA and also via inhibition of PGE synthase [93]. Due to its 3 double bonds, EPA is converted into 3-series PGs by the action of the COX enzymes. Data are still limited on the impact of these compounds, but they have shown weaker or antithetic effects on measures of inflammation when compared to PGE2 [ 16]. One possible impediment to this role of EPA is the consumption of preformed AA in the diet. Consumption of preformed AA, even in the presence of equal amounts of EPA, may lead 
to increased amounts of AA in tissue phospholipids [14, 94]. This may be problematic in 
developed countries such as the U.S. where consumption of meat and animal products is 
high, leading to consumption of relevant quantities of AA [95, 96]. 
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D. PGE2 Production and Signaling 
One of the most thoroughly researched metabolites of AA is PGE2 • It is a potent mediator of inflammation, produces local pain hypersensitivity, plays a role in fever and 
ovulation, and is associated with tumor promotion/survival and osteoporosis as well as 
many other normal and abnormal processes [18, 97, 98]. PGE2 is formed as a result of PGE synthase (PGES) action on PGH2 (see Fig. 4 on page 12). Two isoforms of PGES exist: cytosolic and membrane-associated. The cytosolic form is expressed in most cells 
and tissues and is predominantly coupled to COX-1. The membrane-associated form 
appears to be inducible and is preferentially linked to COX-2 [98]. Once formed, PGE2 then acts in an autocrine or paracrine fashion via one of four receptor (EP) subtypes 
designated EP1 through EP4 (Table 3). The discovery and cloning of these receptor subtypes provided an explanation for the discordant effects of PGE2, such as smooth muscle relaxation in some tissues and potent constriction in others [99, 100]. The EP1 receptor is highly expressed in kidney, gastric mucosa and adrenal tissue, and activation 
results in signaling via inositol triphosphate (IP3) generation and increased levels of intracellular calcium [ 101, 102]. Acting through the same signaling mechanism, activation of EP2 or EP4 results in increased levels of cAMP via stimulatory G-protein coupled receptors. Tissues high in EP2 receptors include the uterus, lung and spleen. Tissues high in EP 4 receptors include the thymus, lung, spleen, adrenal, and kidney [ 101-105]. Activation of EP3 results in inhibition of cAMP production via the inhibitory G­
protein coupled receptors, with this receptor highly expressed in kidney, uterus, adrenal, and stomach tissue [ 102, 106]. The complex interplay of the COX enzymes, three sub­types of PGE, and four sub-types of its receptor have made teasing out the function of each individual protein or compound most difficult. The dynamic and compensatory 
nature of the enzymes, fatty acids, and their metabolites means that isolating one to study 
its function and mechanisms may cause abnormal alterations of others leading to 


































































































































































































































































IV. ADIPOCYTES AND PROSTAGLANDINS 
A. Functions of Adipose Tissue 
Adipose tissue was traditionally considered a passive tissue whose main role was 
energy storage in the form of triglycerides. It is now well established that contrary to this 
belief, adipose tissue is in fact a secretory tissue with the potential to impact multiple tissues and pathways. Serving in an endocrine and autocrine/paracrine role, adipose 
tissue secretes compounds such as leptin, angiotensinogen, adiponectin, PGs such as 
PGE2 and PGI2, cytokines such as tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6), and acylation stimulating protein (ASP). These compounds act upon the 
secreting or neighboring cells and/or distant tissues to impact functions such as appetite 
and energy balance, immune function, insulin sensitivity and cardiovascular function 
[107-114]. Clarification and further understanding of the functions of these bioactive 
compounds, as well as the implications of adipocyte hypertrophy and hyperplasia on their secretion, is vital to understanding the etiology of obesity and its prevention/treatment. 
B. 3T3-Ll Cells 
The 3T3-Ll cell line is clonally isolated from Swiss 3T3 cells originally derived 
form 17-19 day old mouse embryos [115], and is one of the most commonly used cell lines to study adipocyte biology and function. These cells are fibroblasts or preadipocytes that are committed to adipocyte lineage. When grown in culture to confluence, they can be differentiated into mature adipocytes by supplementing culture 
media with dexamethasone (Dex) and methylisobutylxanthine (Mix) with or without 
insulin [ 116]. The differentiation process results in the cell morphology changing to a spherical shape, accumulation of lipid droplets, and other genetic and biochemical 
changes associated with the development of the mature adipocyte [ 115]. Addition of 
insulin to the differentiation cocktail serves to accelerate lipid accumulation and results in 
larger adipocytes. During and after differentiation, activities of enzymes involved in 
triglyceride synthesis are upregulated and the cells become responsive to insulin and 
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other hormones, making them excellent models for the study of mammalian adipogenesis 
[ 116-118] .  In addition, biochemical and genetic conditions in the cell can be compared 
pre-and post-differentiation to help understand the process itself. This quality makes 3T3-Ll adipocytes an ideal choice for the study of adipocyte development and its role in obesity. 
C. PGE2 and EP Receptors 
Numerous studies have demonstrated that adipose tissue and adipocytes in culture have the capacity to secrete PGE2 under basal conditions and when stimulated by compounds such as catecholamines, theophylline, and the calcium ionophore A23187 
[16, 81, 113, 119] . There was some controversy, however, as to whether prostaglandins produced from adipose tissue explants were produced by the adipocytes or were in fact 
produced by blood vessels and other non-adipose cells found within adipose tissue [120]. 
Recent work in human adipose tissue explants has demonstrated that human adipocytes 
do secrete PGE2 [23, 81] . Adipocytes digested and maintained in culture secreted levels approximately 4% of tissue explants, while cultured adipocytes secreted levels 
approximately 38% that of tissue explants when both were exposed to endogenous AA [81]. In cultured 3T3-Ll cells, production of PGE2 was several fold higher in preadipocytes compared to adipocytes, although it was still the main PG secreted during all stages of cell development [113]. In order for PGE2 to act in an autocrine/paracrine fashion, adipocytes must also express one or more of the EP receptors. Receptors capable of binding PGE 1 were first demonstrated in rat adipocytes [121, 122]. Subsequent studies have demonstrated the expression ofEP1 , EP3 , and EP4 receptors in OB 1 771 preadipocytes as well as mouse precursor cells and mature adipocytes [ 123] . 
Studies conducted on human adipocytes indicated the presence of two or more PGE2 binding sites with different affinities, but did not identify the receptors [13]. Taken 
together, these studies indicate that PGE2 secreted by adipocytes is capable of acting in an autocrine/paracrine manor to regulate adipocyte metabolism. 
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D. PGE2 Effects On Adipocytes 
The primary and most immediate effect of PGE2 on adipocyte metabolism is the 
inhibition of lipolysis through a reduction in cAMP [ 1 3 , 1 24, 1 25] ,  most likely mediated 
through interaction with the EP3 receptor [ 126] . Further evidence indicated that the 
major impact of PGE2 was on mature adipocytes versus preadipocytes, and that EP3 
receptor mRNA was expressed only in mature adipocytes [ 1 23, 127] .  Lipolysis has 
displayed a biphasic response to PGE2 , with high levels stimulating this process [ 1 28] ,  
although this study has been refuted on the grounds that the antilipolytic action of 
adenosine was not controlled for in the earlier study [ 1 29] . Concurrent with a decrease in 
lipolysis, PGE2 was also found to stimulate leptin release in primary cultures of mouse 
adipose tissue. Both effects were partially reversed by the administration ofNS-398, a 
selective COX-2 inhibitor [ 1 30] . PGE2 may also play a role in modulating adipocyte 
gene expression independent from its parent compound AA. Spot 14  is a nuclear protein 
found primarily in lipogenic tissues, and has been shown to increase in a manner that 
correlates with expression of lipogenic genes [ 1 3 1 ] .  In 3T3-Ll cultures, AA was shown 
to suppress S 14 and FAS mRNAs as has been demonstrated with other PUF As, but the 
activity on S 14  expression was reversed by the addition of a COX inhibitor. PGE2 at a 
dose of 1 0  µM replicated this suppression via a pertussis toxin sensitive alteration in 
cAMP levels [ 1 32] . Additional experiments looking at the effects of PGE 1 , PGE2, and 
PGE3 on PP AR isofonns found no effect for any of the PGE variants in activation of 
these transcription factors [ 1 33 ] .  It is clear that PGE2 can and does impact the metabolic 
processes of lipolysis and lipogenesis in adipose tissue. What is not clear is the exact 
mechanism. The presence of multiple isoforms of the EP receptor that are capable of 
initiating similar, divergent or opposing signaling pathways makes it difficult to elucidate 
the actions of PGE2 , and may indicate a host of actions depending on the physiological 
conditions at the time. We therefore set out to clarify whether there is a specific role for 




PROSTAGLANDIN E2 SECRETION AND EFFECT ON MARKERS OF 
LIPOGENESIS 
I. ABSTRACT 
A dramatic rise in the incidence of obesity in the U.S. has accelerated the search for interventions that may impact this epidemic. Prostaglandin E2 (PGE2) has been shown to decrease lipolysis in adipocytes. Preliminary work conducted in our lab on 
mice has also demonstrated a potential role for PGE2 in increasing the activity of a lipogenic enzyme, fatty acid synthase (FAS). Taken together, these two actions would 
lead to an increased accumulation of triglycerol in the adipocyte and increased adiposity. From a dietary standpoint, one potential means of manipulating levels of PGE2, and possibly adipose tissue levels, is by increasing the consumption of preformed eicosapentaenoic acid (EPA) in the diet. The purpose of this study was to determine 
whether the concentration of PGE2, and lipogenesis as measured by FAS activity, could be decreased by the addition of EPA or a selective COX-2 inhibitor. All studies were conducted using cultures of differentiated 3T3-Ll adipocytes. Dose response studies 
determined that 150 µM concentrations of AA and EPA resulted in approximately a 5-
fold difference in PGE2 secretion between the two treatments. Despite effectively mediating the production of PGE2 (p<0.05), the addition of EPA resulted in no significant decrease in FAS activity. Addition of celecoxib, a selective COX-2 inhibitor, also 
significantly decreased PGE2 secretion {p<0.05) and did result in a significant decrease in FAS activity (p<0.05). Unexpectedly, the combination of exogenous PGE2 and celecoxib further decreased the FAS activity compared to PGE2 alone or untreated controls. In conclusion, competitive inhibition of AA metabolism by EPA results in significantly 
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decreased production of PGE2 when compared to AA treatment, but no significant decrease in FAS activity. Selective inhibition of the COX-2 enzyme also significantly decreases PGE2 production resulting in a decrease in FAS activity that is not reversed with the addition of exogenous PGE2, suggesting an additional mechanism that is not mediated by COX-2. 
II. INTRODUCTION 
The demonstration of endocrine roles for adipocytes has provided new insights 
helping to explain the etiology of obesity. The secretion of prostaglandins such as PGE2 has been demonstrated in human and rodent adipocytes [16, 81, 113, 119]. The presence of PGE2 receptors in these tissues as well [121-123] has led to research into a possible autocrine or paracrine role for this AA metabolite. Several groups have shown that 
endogenous PGE2 decreases lipolysis in cultured adipocytes and explants [13, 124, 125], most likely acting through a G-inhibitory protein-coupled EP3 receptor [126], confirming 
a paracrine/autocrine role of PGE2 in adipocytes. Several other roles for PGE2 in adipocytes have been investigated and include regulation of leptin release and lipogenic 
gene expression [11, 12]. Growth of adipose tissue is accomplished by increases in adipocyte size 
(hypertrophy) and number (hyperplasia) [134], and is a hallmark of obesity. Increases in 
adipocyte size are accompanied by an increase in stored lipids in the form of 
triglycerides, which can be formed from circulating lipids or de novo lipogenesis [135]. To support de nova lipogenesis, glucose must be present to form the glycerol backbone of 
the triglyceride, and enzymes of lipogenesis must be present to generate the fatty acids. AA acid has been shown to stimulate glucose intake in adipocytes by increasing glucose 
receptor levels in the cell membranes [ 136]. AA is also the preferential substrate for the 
COX enzymes and the resultant production of PGs [10, 89]. In mature adipocytes, PGE2 is the primary PG produced from the COX pathway [113, 119]. Preliminary evidence 
from our laboratory conducted on adipose tissue samples from ApcMinl+ mice [ 18] indicated a possible role for PGE2 in increasing FAS activity, an indicator of lipogenesis. 
2 1  
Further, adipose tissue from mice given the non-specific COX inhibitor piroxicam or sulindac showed significantly decreased FAS activity versus controls, while the addition of PGE2 receptor agonists partially and significantly reversed this effect [137]. Coupled with the known effect of PGE2 in decreasing lipolysis, this effect on FAS activity would lead to increased adipocyte triglyceride accumulation and hypertrophy. 
Dietary EPA has demonstrated the capacity to impact adipocyte biological functions via two distinct mechanisms. The first is via transcription factors that impact 
the expression of genes involved in differentiation and lipogenesis. The second mechanism is via direct competition with AA for incorporation into membrane 
phospholipids and subsequent conversion to eicosanoids such as PGs via the COX 
enzymes. The first mechanism has been extensively studied, while few studies have addressed the second mechanism. The PGs (specifically PGE3) produced by the COX 
action on EPA appear to have weaker action when compared to those produced by AA 
(PGE2}, making displacement of AA by EPA a favorable outcome for attempts to control excess adiposity. 
Inhibition of AA metabolism to PGs can also be accomplished via 
pharmacological intervention, and may provide a more direct mechanism to impact PGE2 actions. Compounds known to inhibit both isoforms of the COX enzymes, as well as 
selective COX-2 inhibitors, have been shown to reduce PGE2 production in adipocytes [2 1 -23, 81], and represent a second means to modulate PGE2 levels and investigate the impact on lipogenesis. The objective of this work is to investigate the impact of PGE2 on fatty acid synthesis via regulation of the FAS enzyme. We hypothesized that addition of EPA or 
selective COX-2 inhibition would lead to a decrease in PGE2 production and subsequent downregulation of markers of lipogenesis such as FAS enzyme activity (Fig. 6). 
III. MATERIALS AND METHODS 
A. Animals 






Figure 6. Proposed Mechanism of Action for Decreased PGE2 Secretion Via 
EPA Competition 
Gray arrows indicate autocrine function of PGE2/PGE3. Bold arrows indicate 
known/proposed EPA mediated changes in PGE2 metabolism and action in adipocytes 
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days of age. They were housed in a temperature-controlled room with 14 h periods of 
light and 10 h periods of darkness and given free access to food and water. The health of 
the animals was checked daily. Food was withheld overnight prior to sacrifice. All animal procedures were approved by the University of Tennessee Animal Care and Use Committee and were in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (National Research Council, 1985) 
B. Diets 
Diets were composed of purified AIN93-G powder diet (Dyets, Inc., Bethlehem, PA). Experimental diets containing NSAIDs were prepared daily by thoroughly mixing 
piroxicam (Sigma, St. Louis, MO) with the control diet. Diets were stored at -20°C and 
all animals were provided fresh food daily. Food consumption was monitored daily and 
body weights were recorded weekly. 
C. 3T3-Ll Cell Culture 
Cells were purchased from American Type Culture Collection (ATCC, Rockville, MD) and were grown in 100 mm dishes. Culture medium was composed ofDulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (PBS) and 1 % penicillin/streptomycin (P/S). Cells were plated on day 1 (-200,000 cells/! 00 mm dish) and grown for 3-4 days to confluence. At confluence, media was changed and supplemented with 250 nM Dex, 0.5 mM Mix, and 10 nM insulin for 48 h to induce adipocyte differentiation, after which cells were cultured with regular media. Differentiation was considered complete at 5-7 days post-confluence (see Fig. 7 for time 
line). Twenty-four hours prior to treatment, regular media was replaced with starvation 
media consisting of DMEM, PIS, and 1 % fatty acid free bovine serum albumin (BSA). 
Treatment media consisted of starvation media + 10 nM insulin and individual (FA or 






























































































































































D. Experiment Design 
Experiment 1 Male C57BL/6J ApcMinl+ mice were maintained on the AIN-93G 
diet until 78-79 days of age at which time they were randomly assigned to one of four 
groups { control, E-prostaglandin receptor agonist (EPR-A), piroxicam, or piroxicam + 
EPR-A} .  Groups receiving piroxicam (0.5  mg/mouse/day) were pair fed to ensure 
equivalent dosing. The EPR-A, 16,16-dimethyl-PGE2 and 17-phenyl-trinor PGE2 
(Cayman Chemical, Ann Arbor, Ml), were administered as 10 µg each in sterile 
phosphate buffered saline. The EPR-A or vehicle was administered in two daily IP 
injections (0800, 1600) and once daily via gavage feeding (1200) to maximize exposure 
to the GI tract over a 6 day period. Primary care and feeding of the mice was conducted 
by Dr. Jay Whelan's lab in conjunction with his study on the role of PGE2 and colon 
cancer [18] .  The mice were sacrificed at 85-86 days of age by cervical dislocation and 
epididymal adipose tissue was harvested, weighed, snap frozen in liquid nitrogen and 
stored at -80°C. Liver weights were also obtained at the time of harvest. 
Experiment 2 The goal of our dose response studies was to find a dose of EPA 
that would significantly reduce PGE2 levels when compared to an equivalent 
concentration of AA, while remaining physiologically relevant. 3T3-Ll cell cultures 
were grown as above, and then treated with AA or EPA (Nu-Check Prep, Inc., Elysian, 
MN) in 25, 50, 100, 200, and 500 µM doses. Two hours prior to treatment, fatty acids 
were diluted to the appropriate concentration with dimethyl sulfoxide (DMSO), and then 
added to treatment media and agitated in a shaking water bath at 3 7°C to facilitate FA 
binding to BSA. Treatment time was 48 h for all doses. Two mL of media was removed 
from each dish prior to cell harvest for analysis of PGE2 levels. Cell cultures were 
harvested for cytosolic extracts. 
Experiment 3 This control experiment was conducted to verify that changes in 
PGE from adipocyte cultures treated with EPA were enzymatically driven. 3T3-Ll cell 
cultures were treated with EPA (50 µM and 150 µM concentrations), the selective 
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COX-2 inhibitor celecoxib (CI) (5 µM) (Pharmacia, St. Louis, MO), and EPA (1 50 µM) 
+ CI (5 µM). In addition, culture media with EPA at 1 50 µM concentration was exposed 
to cell culture conditions to facilitate lipid peroxidation. 48 hours following treatments, 
two mL of media was removed from each dish to measure PGE2 levels and cells were 
harvested for cytosolic extracts. 
Experiment 4 The role of PGE2 in regulating the activity of the FAS enzyme 
was investigated using 3T3-Ll cell cultures. Cell cultures were treated with vehicle 
(DMSO), CI (1 µM), OA, EPA, AA, ( 1 50 µM each treatment) or AA + EPA (75 µM 
each fatty acid). All fatty acids were added to treatment media and agitated in a shaking 
water bath for 2 h at 37°C prior to treatment of cells to facilitate binding to BSA. 
Treatment time was 48 hours. Two mL of media was removed from each dish, and cell 
cultures were harvested for cytosolic extracts or total RNA. 
Experiment 5 To verify that PGE2 was responsible for the decrease in FAS 
activity seen with selective COX-2 suppression, PGE2 was added back to mean levels 
measured in the control groups of previous experiments. 3T3-Ll cell cultures were 
treated with vehicle (DMSO), CI (1 µM), PGE2 (300 pM) (Cayman Chemical, Ann 
Arbor, MI), and CI + PGE2• 48 hours following treatment, two mL of media was 
removed from each dish, and cells were harvested for cytosolic extracts or total RNA. 
E. Methods 
FAS assay The activity of FAS was determined in cytosolic extracts from mouse 
adipose tissue and cell culture by measuring the rate of oxidation of NADPH [ 138 ] .  
Mouse adipose tissue collected from experiment 1 was homogenized on ice in 500 µL of 
buffer (pH 7.4) containing 250 mM sucrose, 1 mM dithiothreitol, 1 mM EDTA, and 0. 1 
mM phenylmethylsulfonyl fluoride (PMSF) for -- 30 seconds. Tissue homogenates were 
centrifuged for lh  ( 12,000 x g) at 4°C. The supernatant was then removed for analysis 
of FAS activity and protein concentration. Cell culture plates harvested for cytosolic 
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extracts were washed twice in Hank's balanced salt solution, and then scraped using 350 
µL of the buffer described above. Cell homogenates were sonicated on ice for 5 seconds 
and centrifuged for lh  (12,000 x g) at 4°C. The supernatant was then removed for 
analysis of FAS activity and protein concentration. 
Oxidized NADPH absorbs light at a wavelength of 340 nm. The absorption change over a 5-minute time period was measured spectrophotometrically (Spectronic Genesys 5) and was used to calculate the nmol ofNADPH oxidized per minute. These 
values were corrected for protein concentration. 
Protein assay Protein concentration was determined in cytosolic extracts by the 
method of Bradford [139]. This assay utilizes the dye Coomassie blue (Bio-Rad, 
Melville, NY), which has an affinity for basic and aromatic amino acids. The normally 
red-brown dye absorbs light at 470 nm, but changes to a blue color when it binds to 
amino acids and the absorption spectrum changes to 595 nm. Each sample was measured 
in duplicate using 10 µL of sample and 200 µL of dye in a 96-well plate. After addition 
of the dye, the samples were incubated for 5 minutes and read in a spectrophotometer at 
590 nm. A standard curve was plotted using serial dilutions of a BSA standard of known concentration and sample concentrations were extrapolated based on this standard curve. 
PGE2 assay Cell culture PGE2 concentrations were determined using culture media samples obtained immediately prior to cell harvest. PGE2 levels were measured by enzyme immunoassay (EIA) using the Correlate-BIA PGEi Kit (Assay Designs, Ann Arbor, MD according to the manufacturer's instructions. A standard curve was plotted using serial dilutions of a known concentration of PGE2 and sample concentrations were extrapolated based on this standard curve. 
Leptin assay Cell culture media samples were utilized in an attempt to measure 
leptin levels. Initial attempts at measurement indicated very low leptin levels. 
Centrifugal concentration was conducted using centricon® YM-3 filters (Millipore, 
Billerica, MA) centrifuged at 7 500 x g for 2 hours. Leptin measurement was attempted 
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by two different methods. Radioimmunoassay (RIA) is a competitive protein-binding 
assay, which utilizes a radio labeled antigen (hormone) that competes with unlabeled 
hormone in the sample for binding sites on an antibody. Measurement of radioactive 
hormone bound to the antibody determines the amount of antigen present. This is 
compared to a standard curve calculated from known concentrations of hormone to 
determine the concentration of leptin. The RIA kit was purchased from Linco Research 
(St. Charles, MO). Samples were 100 µL and were tested in duplicate. The second 
method attempted, Enzyme Immuno Assay (EIA) utilizing the Mouse Leptin ELISA Kit (Crystal Chem. Inc., Downers Grove, IL), utilized a more sensitive assay to detect the 
presence of leptin. The assay was conducted using the manufacturer's instruction. 
Sample volume was 5 µL with samples tested in duplicate. A standard curve was 
constructed using samples of know concentration to determine leptin levels in culture 
media. 
Real time RT-PCR Real time RT-PCR utilizes fluorescent dyes to allow quick 
and accurate quantification of mRNA, and is more sensitive than Northern blot methods 
[ 140] . A probe is used that is designed to bind specifically to the target mRNA 
sequence. This probe is labeled with 2 dyes: a fluorescent reporter dye on the 3' end and 
a quencher dye on the 5 '  end. When no target sequence is bound, the quencher dye 
resides in close proximity to the reporter dye and no fluorescence is detected. When a target sequence is present, the probe will bind it and the distance between the two dyes is 
extended to the point where fluorescence can now be detected. The intensity of fluorescence thus increases directly with an increase in the number of target mRNA sequences, which will reflect gene expression levels. FAS mRNA expression was determined using this method. Cells harvested for 
total RNA were scraped in 350 µL of Qiazol lysis reagent (Qiagen, Valencia, CA) and 
sonicated on ice for 5 seconds. RNA was extracted using the RNeasy™ lipid tissue midi 
kit (Qiagen) following the manufacturer's protocol. RNA was stored at -80°C for use in 
real time RT -PCR and microarray analysis. 
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The primers were ordered from Invitrogen (Carlsbad, CA). The sequence of the forward primer is 5 'CCCAGAGGCTTGTGCTGACT 3'. The sequence of the reverse 
primer is 5 'CGAATGTGCTTGGCTTGGT 3' .  The probe was ordered from Biosearch Technologies, Inc. (Novato, CA). The sequence of the probe is 5 '  (TET)CCGATCTG GAA TCCGCACCGG{T AMRA) 3 ' .  TET is the quencher dye that inhibits the 
fluorescence of the reporter dye when in close proximity. TAMRA is the reporter dye and is measured at a wavelength of 580 nm. The SmartCycler SCl000-1 and SmartCycler software (Cepheid, Sunnyvale, CA) were programmed as indicated in Table 4. 
Microarray analysis Microarray analysis is a relatively new technology used to measure gene expression by determining the amount of mRNA present in a sample [ 141]. 
This is usually done for the gene or genes of interest by comparing the expression of the gene(s) in a treatment group versus the expression of the same gene(s) in the control 
group. The foundation of this technology is a glass slide or "chip" that can contain up to 
450,000 spots composed of complimentary DNA ( cDNA) sequences for specific genes. mRNA samples from the control and 1 treatment group are converted to cDNA and 
labeled with a separate dye (normally green for control and red for treatment). The 
cDNA from each sample is placed on the same slide and incubated for 16-20 hours at 
42°C. The slides are then washed and scanned by a laser that measures the intensity of each spot. 
Table 4. RT-PCR Programming Menu 
Stage Temperature Time (seconds) Number of Cycles 
1 48°C 1,800 1 
2 9s0c 600 1 
9s
0
c 15 3 40 60°C 60 
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Genes expressed by both the control and treatment will display approximately 
equal intensity of both colors, while a gene expressed predominantly by the control or 
treatment will display an intensity equal to that of the dye it was labeled with. The laser 
generates separate files with the intensity of the red and green dye for each spot on the 
chip. This data is then uploaded to software that combines the two files and displays the 
intensity of each spot. This is then used to calculate gene expression for treatment 
relative to the control. 
Mouse cDNA microarray slides spotted with 15K mouse genes/expressed 
sequence tags (EST) in duplicate were obtained from University Health Network 
Microarray Center, Toronto, Canada. Total RNA from the control, CI, AA, EPA, AA + 
EPA groups in experiment 3 were labeled with Cy3 (control) and Cy 5 (treatments) dUTP 
dyes (Perkin Elmer, Shelton, CT). Hybridization was performed using the protocol 
developed by The Institute of Genomic Research [142]. The slides were scanned with a 
GSI 4000 scanner from GSI Lumonics (Perkin Elmer) and stored as TIFF files. The 
scanned images were merged using ScanAlyze software ( developed at Stanford 
University) and uploaded into the Stanford Microarray Database (SMD) [143] installed at 
the University of Tennessee for analysis. Intensity values for each spot were normalized 
for background intensity and transformed logarithmically (base 2). Expression values are 
given as a ratio of red/green (treatment/control) intensity, with inter and intra experiment 
values for the same gene being averaged (control, CI, AA, EPA n = 4; AA + EPA n = 2) 
to obtain reported gene expression levels. For the purpose of this thesis, microarray 
analysis was only used to screen expression of a limited number of genes of interest. 
These genes include FAS, glucose transporters 1 and 4 (GLUTl,  GLUT4), SREBP, 
prostaglandin E synthase (PGES), and two of the prostaglandin E receptor isoforms (EP2 
and EP4). 
Statistics Statistical analysis for all assays was conducted using SPSS (SPSS for 
windows, version 12.0, SPSS Inc., Chicago, IL). Data were analyzed for homogeneity of 
variance and for significant F ratios between treatment groups using one-way analysis of 
variance (ANOV A). Post-hoc analysis was conducted using the Bonferroni ( equal 
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variance) or Dunnett's  T3 (unequal variance) test when significant differences were detected. All values are expressed as mean ± SEM. Values ofp<0.05 were considered statistically significant except where otherwise noted. 
Statistical analysis for microarray was conducted using SAS (Cary, NC) on log 
base 2 values. Outliers defined as observations > 10 times the median absolute deviation away from the median were discarded. Normalization was done with a loess smoothing parameter of 0.3. Normalized and corrected data were analyzed with SAS mixed models [144], including the random effect of array and fixed effect of dye. Differences in means 
on the log scale are equivalent to ratios of gene expression, and the latter from SMD are reported in the appendix. 
IV. RESULTS 
Experiment 1. Effect of COX inhibition and EP receptor agonists in mouse adipose 
tissue 
This experiment was conducted as preliminary work to assist in defining a role for COX specific products in modulating FAS activity. Non-specific inhibition of the COX enzymes with piroxicam resulted in decreased FAS activity (p<0.02), while piroxicam + 
EP receptor agonists resulted in significant partial restoration of FAS activity (p<0.02) 
(Fig. 8). Treatment with EP receptor agonists alone also resulted in a significant reduction in FAS activity when compared to control (p<0.02). 
Experiment 2. Dose-Response effect of EPA and AA on PGE2 secretion in 3T3-Ll 
adipocytes 
Consistent with studies that have shown the displacement of AA by EPA in tissue 







0 ... c.. 
OIJ 
s - 1 5.0 
s 
C -



























Piroxcam + PGE2 
Receptor Agonist 
Figure 8. Effects of Piroxicam and PGE2 Receptor Agonists On FAS 
Activity In Adipose Tissue From ApcMinl+ Mice 
n = 6 for C and P + EPRA; n = 5 for P and EPRA 
Values labeled with different letters are significantly different (p<0.02). Values with the 
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Figure 9. Dose-Response Effects of AA and EPA On PGE2 Levels In 
3T3-Ll Adipocytes 
n = 5 for AA/EPA 500; n = 1 0  for C and AA/EPA 25 ; n = 1 5  for AA/EPA 50, 1 00, 200 
Values labeled with different letters are significantly different (p<0.03). Values with the 
same letters do not differ significantly. 
+ Values for AA 500 µM were beyond the accurate working range of the assay therefore 
no value is expressed. 
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attributed to PGE2 EIA assay cross- reactivity for PGE3 , which is reported by the manufacturer to be 16.3%. FAS enzyme activity was analyzed for the various doses of 
EPA and AA and displayed no significant changes when compared to control (Fig. 10) 
except for AA 500 µM (p<0.03). 
Experiment 3. Effect of EPA + CI treatment on measured PGE levels in cultured 
3T3-Ll adipocytes 
Addition of CI and EPA (150 µM) led to a significant reduction in measured PGE 
activity (p<0.09) (Fig. 11 ). This data recapitulates our previous experiment and 
demonstrates that the PGE formation is an enzymatic process, supporting the suggestion that the increased levels measured in EPA treated cell cultures are a result of PGE3 formation. PGE levels for the other treatments used in this experiment were in line with 
what has been seen in our previous experiments. 
Experiment 4. Effect of selective COX-2 inhibition and EPA addition on PGE2 
levels, FAS activity and FAS mRNA levels in 3T3-Ll adipocytes PGE2 levels were effectively reduced compared to control by the addition of CI (p<0.001). All fatty acid treatments resulted in measured increases in concentrations of 
PGE2 compared to control, with concentrations increasing in the order of OA (p<0.05), < EPA < AA +  EPA < AA (all p<0.001) (Fig. 12). Consistent with the decrease in PGE2 levels, FAS enzyme activity was significantly decreased by treatment with CI (p<0.05). 
Treatment with EPA and AA resulted in trends similar to those seen from the dose­response study but did not reach statistical significance (Fig. 13). Attempts to measure leptin levels in culture media consistently resulted in concentrations just at or below the minimum sensitivity of both methods attempted. After several trials that included different cultures and culture conditions, we concluded that leptin levels were too low to be used as a marker for our studies and therefore did not include measurements of media 
leptin levels in this thesis. Expression of FAS mRNA analyzed by real time RT-PCR and 
microarray showed a significantly decreased expression for all FA treatments versus control (p<0.05) (Fig. 14). The level of reduction of FAS mRNA for the FA treatments 
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Figure 10. Dose-Response Effects of AA and EPA On FAS Activity In 
3T3-Ll Adipocytes 
n = 5 for AA/EPA 500; n = 10 for C and AA/EPA 25 ; n = 15 for AA/EPA 50, 100, 200 
Values labeled with different letters are significantly different (p<0.03). Values with the 
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Figure 1 1 . PGE2 Levels of Cell Culture Media and 3T3-Ll Cell 
Cultures Treated With EPA and CI 
n = 4 for C; n = 3 for all other treatments 
* Denotes culture media exposed to cell culture conditions without cells. 
Values labeled with different letters are significantly different (p<0.09). Values with the 
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Figure 12. Effects of COX-2 Inhibition and EPA Addition On PGE2 
Levels In 3T3-Ll Adipocytes 
n = 1 0  for all treatment groups 
Values labeled with different letters are significantly different (p<0.05). Values with the 
same letters do not differ significantly. 
3 8  
=12.0 
] 1 1 .0 
-� 1 0.0 
0 
a 9.o 
a 8 .0 
0 7.0 
s= 6.0 
1 5 .0 
-� "'0 4.0 -� 
0 3.0 
= � 2.0 





a a a 
,� ,- -
I a,b -L...., a,b 
T - I 
b -- _j_ M 





! • - I -
I i 
,  - -,;;, 
:i !� "' -
f. I� 
�; 1;' ,ij ,Jt I& I ½,, w iM :}; 01 I 
I I I I ' I 
C CI OA AA EPA A+E 
Treatment 
Figure 13. Effects of COX-2 Inhibition and EPA Addition On FAS Activity 
In 3T3-Ll Adipocytes 
n = 1 0  for all treatment groups 
Values labeled with different letters are significantly different (p<0.05). Values with the 
same letters do not differ significantly. 
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Figure 14. Expression Levels of FAS mRNA In Cultured 3T3-Ll Cells 
Treated With CI, AA, EPA, or AA +  EPA Versus Control 
n = 6 for all treatment groups 
Values labeled with letters are significantly different from control (p<0.05). Values with 
the same letters do not differ significantly. 
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correlates well with the degree of unsaturation and chain length and may therefore reflect 
a non-specific PUFA effect [70, 72]. 
Experiment 5. Effect of exogenously added PGE2 on selective COX-2 inhibition of 
endogenous PGE2 secretion, FAS activity, and FAS mRNA levels in 3T3-Ll 
adipocytes. 
As demonstrated in our previous experiments, addition of CI resulted in a 
significant decrease in PGE2 production (p<0.04). Addition of PGE2 to cultures with CI­
treated cells restored PGE2 levels and resulted in significantly higher levels versus CI 
treatment alone and versus control (p<0.02) (Fig. 1 5). Addition of PGE2 to cultures 
without CI resulted in the expected significant increase over control levels (p<0.02). The 
level of PGE2 added was based on the mean of previously measured levels of PGE2 
secreted by 3T3-Ll control groups (300 pM). 
Analysis of FAS enzyme activity and mRNA expression, however, produced 
unexpected results. Treatment with CI resulted in a consistent decrease in enzyme 
activity that did not reach statistical significance as in the previous experiments. 
Treatment with CI plus exogenous PGE2 actually resulted in a significant decrease in 
FAS activity (p<0.03) instead of reversing it (Fig. 16). Addition of PGE2 alone, in the 
absence of CI, resulted in no change in FAS activity. Real time RT-PCR analysis of FAS 
mRNA expression indicated that CI treatment had no significant effect in this 
experiment. In contrast, and in agreement with the combined effects of CI and PGE2 on 
FAS activity, FAS mRNA expression was also decreased by the combined treatment vs. 
all other individual treatments (Fig. 1 7). 
V. Discussion 
Despite the vast amount of research that has been conducted on PGE2, much still 
remains to be learned about its impact on adipocyte metabolism. It is well documented 
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Figure 15. Effect of Exogenous PGE2 Addition On PGE2 Concentration 
In Culture Media of 3T3-Ll Cells Treated With and Without CI 
n = 8 for all treatments 
Values labeled with different letters are significantly different (p<0.05). Values with the 
same letters do not differ significantly. 
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Figure 16. Effect of Exogenous PGE2 Addition On FAS Activity In 
Cultured 3T3-Ll Cells Treated With and Without CI 
n = 8 for all treatments 
Values labeled with different letters are significantly different (p<0.04). Values with the 
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With and Without CI On FAS mRNA Expression 
n = 4 for all treatments 
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whether this action was associated with other actions that could be considered anti­
lipolytic or lipogenic. Data from in vivo studies performed in tissues harvested from the 
ApcMinl+ mice clearly indicated that inhibition of the COX enzymes by piroxicam, 
sulindac, or aspirin (unpublished data) led to decreased FAS activity. Reversal of this 
inhibition by EP receptor agonists pointed to a lipogenic role that might be coupled with the decrease in lipolysis already known to occur. Several factors inherent in this study 
required us to continue this investigation in adipocyte models to further delineate possible direct actions of PGE2 in adipocytes. The most prominent shortcoming of these earlier studies was an inherent defect in the Ape gene of this CRC mouse model [ 146], 
potentially contributing to several metabolic inconsistencies that might impact adipocyte 
metabolism. For example, due to their condition, fat mass accretion is typically below that of age-matched controls. These mice also exhibit elevated PGE2 levels associated with high numbers of intestinal tumors [18]. The results found in these studies would 
therefore require verification using other wild type mice models more suited for the study 
of adipocyte metabolism in vivo; or use of adipocyte cell models in culture to determine 
direct cellular and molecular actions of PGE2 in these cells. 3T3-Ll adipocytes were chosen as a model to further investigate the direct actions 
and role for PGE2 in modulating FAS activity. Two separate mechanisms were selected to attempt modulation of PGE2 levels secreted by the adipocytes. Pharmacological intervention utilized celecoxib, a selective COX-2 inhibitor, to inhibit metabolism of AA to PGH2, which we proposed would lead to a decrease in PGE2. EPA was also utilized to competitively inhibit AA metabolism, representing a dietary intervention that we also proposed would decrease adipocyte PGE2 production. Dose response studies demonstrated an approximately linear increase in measured PGE2 levels for AA and EPA, with a highly significant difference (p<0.001) between the two treatments at the 200 µM concentration. Very little information exists in the 
literature regarding physiological levels of EPA. Liebich et al measured free EPA levels 
in plasma using gas chromatography and found them to be approximately 6.6 µM [147]. 
Studies conducted on postmenopausal women fed fish oil found the EPA levels of all 
plasma lipids was 750 µM, and that LDL phospholipids and cholesterol esters contained 
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57.5 nmoVmg protein [84, 145] . Given the approximate ten-fold reduction in measured 
PGE2 levels between EPA and AA at the 1 00 to 200 µM concentrations, 1 50 µM was 
chosen for our dosage. Consistent with the findings of other studies [5, 1 6] ,  we 
demonstrated the ability to manipulate secreted PGE2 by using EPA to compete with AA 
for incorporation into membrane phospholipids and subsequent PG production. 
PGE2 levels in the CI treatment group were significantly lower than controls, 
providing a clear-cut reduction in PGE2 production. Although the CI is a selective 
COX-2 inhibitor, it is uncertain as to the specific mechanism of PGE2 reduction. Most 
published evidence indicates that COX-2 is not expressed at physiologically relevant 
levels in mature adipocytes under normal conditions [2 1 ,  82]. One possible explanation 
for the activity of the CI may be that the IC50 of this compound for COX-1 is reported as 
1 .2 µM [ 148], thus putting our 1 µM concentration high enough to inhibit some COX-1 
function. 
To determine the impact of manipulating PGE2 levels, we used FAS enzyme 
activity as a marker of adipocyte lipogenesis. We report a significant decrease in FAS 
activity with the CI treatment. Lu et al, using aspirin for non-specific COX inhibition, 
have also reported similar effects by measuring accumulation of triacylglycerols in 
adipocytes [2 1 ] , although the duration of their treatment was 6 days making direct 
comparison impossible. 
The overall comparison of PGE2 levels for the AA, EPA, and AA + EPA 
treatment groups correlated well with previously published data measuring tissue 
concentrations of these fatty acids in mice fed diets supplemented with them [5] , although 
the end points measured and experimental models were different [5, 85, 149] . This 
served to help verify that our method of incubating the free fatty acid treatments with the 
fatty acid free BSA did in fact result in the albumin binding the fatty acids, and that the 
fatty acids were being incorporated into the cell membrane phospholipids. 
Although the measured PGE2 levels were significantly lower in EPA 
treatment versus AA treatment, they were still significantly higher than control levels. 
This finding may be partially accounted for by considering PGE3 cross-reactivity, but 
because the actual media content of PGE3 was not measured it is impossible to know the 
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ratio of the PGE isoforms. Complicating this issue further is the fact that very little is 
known concerning the actions of PGE3. Studies in NIH 3T3 fibroblasts found that PGE3 activated the same signaling pathways as PGE2, but with much less efficiency [16]. This 
would imply that high levels of PGE3 may duplicate the actions of PGE2, suggesting there would be a point of diminishing returns with EPA supplementation. It is also 
possible that PGE3 may bind EP receptors with affinities that differ significantly from PGE2 , whereby the type and number of receptors in adipocytes would also influence the impact of EPA supplementation. An additional study was undertaken to verify that the 
measured changes in PGE formation in EPA treated cells was mediated via an enzymatic process. This data recapitulates our previous experiment and demonstrates that the PGE 
formation is an enzymatic process, and since no exogenous AA was added to the cells 
these data collectively support the suggestion that production of PGE3 is responsible for the increases seen in PGE production. It is important to note that measuring enzyme activity only gives a picture of the 
quantity of enzyme present at the time of harvest and does not reflect regulation at other levels such as transcription, translation, and protein half-life that impact the quantity of 
enzyme present and therefore the product formed (in this case F As and subsequently 
triacylglycerols). Since FAS is well documented to be primarily regulated -whether 
nutritionally or hormonally- at the level of gene transcription [ 150-152], we examined the 
impact of our treatments on the genetic regulation of the FAS enzyme using real time RT-PCR and microarray analysis. The use of these small- and large-scale gene analysis 
methods, respectively, relays information regarding the expression of FAS mRNA or other genes of interest for a given treatment relative to the control. Both RT-PCR and 
microarray analysis indicated a clear reduction in FAS mRNA for all treatments versus the control. The effect of fatty acid treatment was substantial, with the reduction correlating well with degree of unsaturation and chain length as previously reported for 
hepatic FAS and other lipogenic gene regulation [153, 154]. This effect also very closely 
resembles results from Deng et al showing that degree of unsaturation correlated highly 
with suppression of the SREBP-l c  promoter [72]. 
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Treatment with EPA and AA led to significantly increased PGE levels versus 
control, yet both treatments suppressed FAS mRNA expression compared to control 
values. Treatment with CI led to reductions in PGE production, yet treatment with CI in 
experiment 4 also led to reduced FAS mRNA when compared to control. These data 
demonstrating opposing changes in PGE levels with similar reductions in FAS mRNA 
seem to indicate nuclear regulation as playing a key role in these changes for AA and 
EPA treatment independent of PGE levels. Since mRNA stability was not measured in 
these experiments, it is possible that increased stability was responsible for the 
discrepancy created by decreased FAS mRNA expression and unchanged FAS activity 
for PUFA treatments. It is also possible this discrepancy is due to a longer half-life of the 
FAS protein such that we were unable to detect changes in enzyme activity within our 
treatment times (24-48 hours). Indeed, previous studies have shown changes in FAS 
mRNA half life depend on cell culture treatment and state of differentiation [ 1 52, 1 55]. 
When exogenous PGE2 was added to cells treated with and without CI, we 
obtained very surprising results. Although PGE2 levels in media were significantly 
higher than controls, FAS activity with PGE2 added to CI was significantly lower than 
controls. This was in direct opposition to what was expected, and what has been shown 
by other experiments [2 1 ]. In addition to the duration of treatment, another possible 
explanation for this result may be linked to leptin secretion. PGE2 was shown to 
stimulate leptin secretion in mouse adipose tissue in primary culture [ 1 30], and elevated 
leptin levels decrease lipogenesis [ 1 56] and specifically impact FAS by decreasing gene 
expression [ 1 57, 1 58]. It is unfortunate we were not able to measure cell culture leptin 
levels, as this would have enabled us to determine whether the exogenous PGE2 did result 
in increased leptin levels. A second possible mechanism involves the antithetic actions of 
the EP receptors. Long et al investigated the role of COX mediated products of AA 
metabolism on regulation of glucose transporter 4 (GLUT 4) regulation. They found that 
a 50-fold increase in endogenous PGE2 or exposure to 1 0  µM exogenous PGE2 resulted 
in an increase in cAMP concentrations, consistent with activation of the EP2/EP 4 receptor 
[ 1 59]. Additionally, studies using the specific COX-2 inhibitor NS-398 on cortical 
collecting duct cells found that NS-398 treatment increased EP3 and EP 4 receptor 
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expression 3-fold [160]. Although the concentration of exogenous PGE2 added in our 
treatments was much lower, our preliminary microarray data indicated that celecoxib also 
influenced the expression ofEP receptors (specifically EP4) and may have resulted in 
findings different from other experiments utilizing aspirin or other non-specific COX 
inhibitors. An increase in EP 4 receptors and the resulting increase in cAMP would 
activate a pathway that would oppose the decrease in cAMP responsible for the PGE2 
mediated decrease in lipolysis. If our hypothesis was correct that this pathway was also 
responsible for an increase in FAS activity, then activating the opposing pathway should 
lead to a decrease in FAS activity. Further work with EP receptor concentration and 
mechanism of action is necessary to delineate the impact of each receptor and how they 
function in a mixed company. 
Measurement ofF AS mRNA expression by RT-PCR showed a reduced 
expression with the CI + PGE2 treatment ( as seen with the enzyme activity), and 
increased expression with treatment by CI alone when compared to control. This result 
also seems to indicate an action of the CI that is further impacted by the addition of 
exogenous PGE2 • This may be tied to EP receptor expression and signaling or may be a 
separate and additional action of the CI acting through regulation of transcription. 
49 
CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
Our studies demonstrated the ability to pharmacologically decrease production of 
PGE2 using the selective COX-2 inhibitor celecoxib, which resulted in a significant 
reduction in measured FAS activity. The use of EPA was also shown to decrease the 
production of PGE when compared to AA treatment, but not when compared to control . 
The PG products resulting from COX action on EPA did p.ot result in a significant 
decrease in FAS enzyme activity, most likely due to higher levels of the two PGE 
isoforms compared to control. Attempts to restore CI reduced FAS activity with 
exogenous PGE2 resulted in further suppression of activity, contrary to what was 
expected. This suggests a possible alternate pathway in the action of the CI treatment 
independent of COX suppression. 
FAS mRNA expression was decreased by FA treatment in a manner similar to 
the PUFA effects seen in liver tissue. Given that SREBPlc, an insulin responsive 
transcription factor, mediates PUFA regulation of hepatic lipogenic genes it is possible 
that PUF A regulation of adipocyte metabolism modulates insulin sensitivity. Indeed, in 
the absence of insulin, our cells expressed significantly higher PGE2 levels than in the 
presence of insulin. 
Further experimentation is required to determine the mechanism of action of 
celecoxib and PGE2 in adipose tissue, and to resolve the seeming inconsistency in the 
role of PGE2 in modulating FAS enzyme activity and mRNA content. While we were 
able to demonstrate regulation of PGE2 levels in adipocytes by n-3 PUF A, we were 
limited by the small responsiveness of the FAS model, especially at the enzyme level. 
Lack of simultaneous analysis of several markers of adipocyte metabolism is a weakness 
in our experiments and should be included in future studies. Finally, additional data on . 
the receptor affinities and actions of PGE3, although difficult to approach at this time 
given the lack of data in this area, is necessary in order to understand the mechanism 
mediating EPA and PGE3 effects on lipid metabolism. 
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We have demonstrated in vitro using a well-accepted model of adipocyte 
metabolism that EPA does reduce tissue AA levels in adipocytes and results in a significant reduction in the PGE2 produced. In addition, pharmacological intervention via inhibition of the COX pathway also resulted in significant inhibition of PGE2 production. Although a direct impact on the activity of FAS was not consistently demonstrated, a reduction in PGE2 levels would still result in less inhibition of lipolysis. Less inhibition of lipolysis, coupled with the other known gene-regulated actions of EPA 
and other polyunsaturated fatty acids, would still favorably impact adipose tissue levels 
and result in decreased adiposity. Given the widespread use of celecoxib as an arthritis medication, and the problem of lack of mobility for many who suffer from arthritis, the 
implication of increased lipolysis and a potential for decreased lipogenesis may prove a 
benefit for those who take it. 
This study also brings to light the need for studies on the function and impact of 
PGE3 in adipocytes to determine if it does in fact elicit the same responses as PGE2. If this is the case, then it may indicate a point of diminishing benefit and the need to specify 
a consumption range instead of recommending minimum consumption levels. 
Understanding the mechanisms involved with EPA metabolism takes on further 
importance with the recent FDA move to allow qualified health claims for omega-3 fatty 
acids [161], as this will most certainly bring more attention to these fatty acids and 
increase their consumption even further. 
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The recent development of microarray analysis has given researchers a tool with 
almost unlimited potential to identify and understand the complex nutrient gene 
interactions that impact obesity. Although microarray analysis was not part of the 
original proposal for this thesis, the opportunity to use this incredible tool was too good 
to pass up. Microarray analysis was conducted following the procedures for experiment 
#3 on two separate occasions. Since each slide had duplicate spots, this gave a total of 4 
values for each gene tested, with the exception of the AA + EPA treatment group which 
only had two values due to insufficient RNA from the second trial. Statistics were run on 
all genes for each treatment, but due to the low number of values (n = 4), no statistical 
significance was found on any of our genes of interest. Despite these results, the 
expression of specific genes in the treatment group relative to the controls provided an 
interesting snapshot of the impact of a given treatment. The following chart gives the 
relative expression of treatment versus control for several genes of interest to this work. 
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Table Al . Microarray Results for Selected Genes. 
Gene Treatment 
CI AA EPA AA+ EPA 
GLUT l 1.11 1.51 * 1.58 1.14* 
GLUT 4 0.84 1.32 0.66 2.21 * 
SREBP 1.20 1.80* 2.80 1.20* 
FAS 0.41 * 0.47* 0.14* 0.24* 
PGES 0.92 1.54 2.03 0.19* 
EP2 0.75 1.83 2.10 1.41 * 
EP4 1.20 3.30 1.98 3.30* 
Values reported are means for 4 spots except for * which indicates mean for 2 spots. 
Values indicate relative expression of each gene versus control, where 1.00 would 
indicate expression identical to control. 
GLUT = glucose transporter SREBP = Sterol regulatory element binding protein FAS = Fatty acid synthase PGES = Prostaglandin E synthase 
EP = Prostaglandin E receptor 
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